Table 3.

Multivariate analysis of factors for the prediction of overall survival.

	β	HR	95.0% CI		P
			Lower	Upper
Gender, (male vs. female)	0.589	1.802	1.102	2.947	0.019
Neutrophil absolute value, (>5.8 vs. ≤5.8 ×109/L)	0.518	1.678	1.053	2.676	0.030
KPS, (<80 vs. ≥80)	0.591	1.806	1.086	2.737	0.023
Hb level, (<120 vs. ≥120 g/L)	0.475	1.608	1.138	2.271	0.007
PLT count, (>220 vs. ≤ 220 ×109/L)	0.470	1.601	1.173	2.185	0.003
No. of chemotherapy cycles, (<4 vs. ≥4)	0.339	1.404	1.014	1.943	0.041
Radiotherapy dose, (<60 vs. ≥60Gy)	0.290	1.336	0.957	1.865	0.089
Total number of metastases, (≥5 vs.<5)	0.318	1.374	0.933	2.025	0.108
WBC count, (≤ 7.6 vs. >7.6 ×109/L)	0.218	1.243	0.841	1.839	0.276
No. of metastatic organs, (≥2 vs. <2)	0.046	1.047	0.697	1.573	0.826
History of smoking, (No vs. Yes)	0.113	1.120	0.714	1.756	0.621
Neutrophil-to-lymphocyte ratio, (>4.30 vs. ≤4.30)	0.170	1.186	0.804	1.747	0.390
LDH, (>165 vs. ≤ 165 IU/L)	0.063	1.065	0.746	1.521	0.729
ALP level, (>99 vs. ≤ 99 IU/L)	0.022	1.022	0.743	1.406	0.895
Lymphocyte absolute value, (≤0.93 vs. >0.93 ×109/L)	0.054	1.055	0.682	1.631	0.810
D-Dimer (≥0.5 vs.<0.5 mg/L)	0.067	1.070	0.786	1.456	0.669
Fibrinogen (>4.50 vs. ≤4.30 g/L)	0.105	1.111	0.786	1.570	0.551
Albumin (≤40 vs. >40 g/L)	0.021	1.021	0.702	1.485	0.914
Brain metastasis (Yes vs. No)	0.177	1.193	0.863	1.649	0.284
Bone metastasis (Yes vs. No)	0.003	1.003	0.703	1.432	0.985
T stage (T1-2 vs, T3-4)	0.029	1.030	0.723	1.467	0.871

CI, confidence interval.